不稳定型心绞痛患者血清HMGB1的水平及临床意义被引量：3

下载PDF

导出

摘要目的检测不稳定型心绞痛患者血清高迁移率族蛋白B1(HMGB1)和炎性因子白介素-2、6的水平,分析这些指标间的关系,并探讨HMGB1检测的临床意义。方法选取确诊并住院治疗的冠心病心绞痛患者70例作为观察组,包括稳定型心绞痛34例,不稳定型心绞痛36例;并取50例健康体检者作为阴性对照(对照组)。采用酶联免疫吸附试验(ELISA)测定不同类型心绞痛患者治疗前后患者血清HMGB1及IL-6、TNF-α的水平,对其关系进行分析。结果不稳定型心绞痛患者血清HMGB1和IL-6、TNF-α水平与稳定型心绞痛患者和对照组比较均显著增高(P<0.05);不稳定型心绞痛患者血清HMGB1和IL-6、TNF-α水平与对照组比较显著增高(P<0.05)。治疗后心绞痛组患者血清HMGB1和IL-6、TNF-α水平较治疗前明显降低(P<0.05),但不稳定型心绞痛患者血清HMGB1和IL-6、TNF-α水平与对照组比较明显升高(P<0.05)。通过相关性分析不稳定型心绞痛患者血清HMGB1与IL-6、TNF-α均存在正相关性(r=0.461,r=0.328,均P<0.05)。结论血清HMGB1参与了不稳定型心绞痛的发生发展,可能与IL-6、TNF-α协同作用有关,检测HMGB1水平有助于不稳定型心绞痛的病情判断及治疗效果评估。

作者张岳雯王小敏刘长江宁佳蔡连锁刘玉茹

机构地区河北省乐亭县医院内二科河北省乐亭县医院药剂科

出处《河北医药》 CAS 2015年第24期3748-3750,共3页 Hebei Medical Journal

关键词心绞痛不稳定型高迁移率族蛋白B1 白介素-6 肿瘤坏死因子-Α

分类号 R541.42 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献3

1胡玉华,徐薇.炎性细胞因子在老年冠心病患者诊断与预后判断中的作用[J].第三军医大学学报,2013,35(11):1173-1175. 被引量：7
2李曼,陆林,沈卫峰.高迁移率族蛋白B1与心血管疾病关系的研究进展[J].国际心血管病杂志,2013,40(4):230-232. 被引量：2
3柯元南,陈纪林.不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南[J].中华心血管病杂志,2007,35(4):295-304. 被引量：2143

二级参考文献66

1李小鹰.阿司匹林在动脉硬化性心血管疾病中的临床应用:中国专家共识(2005)[J].中华心血管病杂志,2006,34(3):281-284. 被引量：194
2Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines(Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol,2002, 40(7) :1366-1374.
3Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J,2002,23 ( 23 ) : 1809 -1840.
4Erhardt L, Herlitz J, Bossaert L, et al. Task force on the management of chest pain. Eur Heart J, 2002, 23 ( 15 ) : 1153-1176.
5CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet, 1996, 348(9038) :1329-1339.
6Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001 , 345 ( 7 ) :494-502.
7Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet, 2001, 358(9281):527-533.
8Simoons ML, GUSTO IV-ACS Investigators. Effect of glycopmtein Ⅱb/Ⅲa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation:the GUSTO IV-ACS randomised trial. Lancet, 2001,357(9272) :1915-1924.
9Platlat Receptor Inhibitor in Ischemic Syndrome Management(PRISM) study investigator. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management ( PRISM )Study Investigators. N Engl J Med, 1998, 338(21 ) :1498-1505.
10Platlat Receptor Inhibitor in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms(PRISM-PLUS) study investigator. Inhibition of the platelet giycoprotein Ⅱb/Ⅲa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med,1998, 338(21) :1488-1497.